Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

@article{Dempster2012RoleOR,
  title={Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.},
  author={David W. Dempster and Cheryl L Lambing and Paul J. Kostenuik and Andreas Grauer},
  journal={Clinical therapeutics},
  year={2012},
  volume={34 3},
  pages={521-36}
}
BACKGROUND Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL). RANKL inhibition therefore represents a novel strategy for reducing remodeling and its effects on fracture risk. OBJECTIVES The goal of this study was to review the preclinical and clinical… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
24 Citations
83 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Five years of denosumab exposure in women with postmenopausalosteoporosis: results fromthe first two years of the FREEDOM extension

  • S Papapoulos, R Chapurlat, C Libanati
  • J Bone Miner Res
  • 2012
1 Excerpt

Morphological basis of bone mineral measurements transient and steady state effects of treatment in osteoporosis

  • AM Parfitt
  • Miner Electrolyte Metab
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…